Single Rising Dose Study of BI 655066 in Patients With Moderate and Severe Psoriasis
Public ClinicalTrials.gov record NCT01577550. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Single Rising i.v. (Stage 1) and s.c. (Stage 2) Doses of BI 655066 in Male and Female Patients With Moderate to Severe Psoriasis (Randomised, Double-blind, Placebo-controlled Within Dose Groups)
Study identification
- NCT ID
- NCT01577550
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- AbbVie
- Industry
- Enrollment
- 39 participants
Conditions and interventions
Conditions
Interventions
- BI 655066 (high i.v. dose) Drug
- BI 655066 (high medium i.v. dose) Drug
- BI 655066 (high s.c. dose) Drug
- BI 655066 (low i.v. dose) Drug
- BI 655066 (low medium i.v. dose) Drug
- BI 655066 (low s.c. dose) Drug
- BI 655066 (very high i.v. dose) Drug
- BI 655066 (very low i.v. dose) Drug
- Placebo, i.v. Drug
- Placebo, s.c. Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 31, 2012
- Primary completion
- Sep 30, 2013
- Completion
- Apr 30, 2014
- Last update posted
- Nov 15, 2016
2012 – 2014
United States locations
- U.S. sites
- 7
- U.S. states
- 6
- U.S. cities
- 7
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 1311.1.0007 Boehringer Ingelheim Investigational Site | Burbank | California | — | — |
| 1311.1.0008 Boehringer Ingelheim Investigational Site | Miami | Florida | — | — |
| 1311.1.0003 Boehringer Ingelheim Investigational Site | Port Orange | Florida | — | — |
| 1311.1.0005 Boehringer Ingelheim Investigational Site | Normal | Illinois | — | — |
| 1311.1.0006 Boehringer Ingelheim Investigational Site | Evansville | Indiana | — | — |
| 1311.1.0004 Boehringer Ingelheim Investigational Site | North Dartmouth | Massachusetts | — | — |
| 1311.1.0002 Boehringer Ingelheim Investigational Site | Pittsburgh | Pennsylvania | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01577550, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 15, 2016 · Synced May 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01577550 live on ClinicalTrials.gov.